MAFLD, assessment of comorbidities and tailored therapy

While some aetiologies can be characterised, a multifactorial disease such as MAFLD requires thorough assessment of comorbidities and severity of concomitant fibrosis to assess a patient’s overall risk....
PUBLISHED IN: World J Gastroenterol 2021

Commentary

While some aetiologies can be characterised, a multifactorial disease such as MAFLD requires thorough assessment of comorbidities and severity of concomitant fibrosis to assess a patient’s overall risk.

In this review, L. Hartl et al. (Medical University of Vienna, Austria) summarise the most recent literature on treatment options for MAFLD and NASH and highlight important considerations to tailor therapy to individual patient’s needs in light of their risk profile.

Share the article
Avatar photo

Dr. D. Beard

DR. D. BEARD is specialist of Nash Pathology

Articles: 191

Leave a Reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES